India Exchange Filings

Gland Pharma Q2 FY27 Board Meeting and Earnings Highlights

Gland Pharma Ltd approves Q2 and H1 FY27 results, with Q2 consolidated revenue of ₹18,335.88 million, up 23% year-on-year

  • Q2 EBITDA margin was 26%; net profit was ₹2,907.56 million, up 58% year-on-year and down 8% sequentially.
  • No exceptional items were reported.
  • Deloitte issued unmodified limited-review reports, noting reliance on management-certified information for two immaterial subsidiaries.
  • The company also released a press release and investor presentation.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.